GSK rectal cancer drug shows positive result in key trial
A treatment for rectal cancer being developed by GSK has shown positive results in interim testing, the pharma…
AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
Company remains on track for a planned December 2026 evaluation of the clinical trial’s primary endpoint OCALA, Fla.,…